| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02426333 | Metastatic Castration Resistant Prostate Cancer | Other: Abiraterone Acetate | Radboud University|Janssen-Cilag Ltd. | Phase 1|Phase 2 | 2015-05-01 | 2016-09-15 |
| NCT01961843 | Prostate Cancer | Drug: Abiraterone|Drug: Prednisone | Massachusetts General Hospital | | 2013-10-01 | 2017-03-16 |
| NCT01735396 | Prostate Cancer | Drug: Abiraterone Acetate | Icahn School of Medicine at Mount Sinai | Phase 2 | 2012-12-01 | 2017-01-09 |
| NCT01199146 | Prostate Cancer | Drug: Abiraterone acetate | University of California, San Francisco|Johnson & Johnson|Cougar Biotechnology, Inc. | Phase 2 | 2010-09-01 | 2015-10-02 |
| NCT02656615 | Prostate Cancer | Drug: abiraterone acetate | Aurelius Omlin|Cantonal Hospital of St. Gallen|University Hospital, Basel, Switzerland | Phase 2 | 2016-01-01 | 2017-03-22 |
| NCT01495910 | 21-hydroxylase Deficiency | Drug: Abiraterone acetate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2011-12-01 | 2014-02-27 |
| NCT02787837 | Prostate Cancer | Drug: Abiraterone | Centro Nacional de Investigaciones Oncologicas CARLOS III | | 2014-05-01 | 2017-03-07 |
| NCT02415621 | Prostate Cancer | Drug: Abiraterone Acetate | H. Lee Moffitt Cancer Center and Research Institute | | 2015-04-01 | 2017-02-06 |
| NCT01655147 | Healthy | Drug: Abiraterone acetate|Drug: Rifampicin | Janssen Research & Development, LLC | Phase 1 | 2012-01-01 | 2013-01-08 |
| NCT01842321 | Breast Cancer | Drug: Abiraterone Acetate | UNICANCER | Phase 2 | 2013-07-01 | 2016-03-17 |
| NCT01637402 | Castration Resistant Prostate Cancer | Drug: Abiraterone Acetate|Drug: Prednisone | Terence Friedlander, MD|Janssen, LP|University of California, San Francisco | Phase 2 | 2013-03-01 | 2016-05-20 |
| NCT02867852 | Salivary Glands Tumors | Drug: Abiraterone acetate | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 | 2015-03-01 | 2016-08-22 |
| NCT02608359 | Prostate Cancer | Drug: Abiraterone Acetate | Johnson & Johnson Private Limited | | 2016-05-31 | 2017-03-12 |
| NCT02125357 | Metastatic Castration-Resistant Prostate Cancer | Drug: Abiraterone acetate|Drug: Enzalutamide | British Columbia Cancer Agency | Phase 2 | 2014-09-01 | 2017-02-01 |
| NCT01940276 | Prostate Cancer | Drug: Abiraterone acetate|Drug: Prednisone | Duke University | Phase 2 | 2013-10-01 | 2016-10-21 |
| NCT01780220 | Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy | Drug: Abiraterone | UNICANCER | Phase 1|Phase 2 | 2012-12-01 | 2013-01-29 |
| NCT01424930 | Prostate Neoplasms|Prostate Cancer | Drug: Abiraterone|Drug: Prednisone | Janssen-Ortho Inc., Canada | Phase 2 | 2011-10-01 | 2014-07-14 |
| NCT00910754 | Prostate Neoplasms | Drug: Abiraterone acetate|Drug: Prednisone | Janssen Research & Development, LLC | Phase 1 | 2009-05-01 | 2013-04-11 |
| NCT02001571 | Prostate Cancer | Drug: Abiraterone acetate | Cougar Biotechnology, Inc. | Phase 1 | 2009-08-01 | 2013-11-28 |
| NCT01678573 | Healthy | Drug: Treatment A: abiraterone acetate|Drug: Treatment B: abiraterone acetate|Drug: Treatment C: abiraterone acetate | Janssen Research & Development, LLC | Phase 1 | 2012-07-01 | 2013-09-05 |
